CardioKinetix Announces Positive Data from Heart Failure Device Trial

CardioKinetix, a California medical device company, reported positive results from a three-month China trial of its minimally invasive heart failure treatment, the Parachute ® Ventricular Partitioning Device. The device, which blocks off non-functioning areas of the left ventricle following a heart attack, helps the damaged heart provide adequate blood flow. In a China trial that enrolled 31 patients, the Parachute device reduced the volume of the left ventricle by one-third at three months, a result that CardioKinetix called "highly significant." More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.